Research progress on interferon λ in chronic hepatitis B
10.3760/cma.j.issn.1674-2397.2020.03.014
- VernacularTitle:IFNλ在乙型肝炎治疗中的意义及相关研究进展
- Author:
Chanyuan YE
1
;
Shanyan ZHANG
;
Xiaoli ZHANG
;
Jueqing GU
;
Yida YANG
Author Information
1. 浙江大学医学院附属第一医院传染病诊治国家重点实验室 国家感染性疾病临床医学研究中心 感染性疾病诊治协同创新中心，杭州 310003
- From:
Chinese Journal of Clinical Infectious Diseases
2020;13(3):228-233
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B is a major public health problem in China. Nucleoside/nucleotide analogues and interferon(IFN) can effectively inhibit the replication of hepatitis B virus, but the treatment effect is still not so effective because cccDNA cannot be completely removed. IFNλ is a newly discovered family of cytokines that induces antiviral, antiproliferative and antitumor effects by activating the Jak-STAT pathway. Recent studies have found that IFNλ is also of great significance in hepatitis B as a therapeutic agent and immunological indicator. IFNλ can effectively inhibit the replication of hepatitis B virus, while the gene polymorphisms of IFNλ are closely related to prognosis and susceptibility to hepatitis B; and IFNλ also shows a certain anti-tumor activity in hepatitis B-related hepatocellular carcinoma. IFNλ is expected to be used as a clinical adjuvant treatment for patients with hepatitis B. This article describes the current research progress on IFNλ in hepatitis B.
